Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.

Background: In pivotal studies, idelalisib demonstrated remarkable efficacy and manageable tolerability in patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). This prospective, multicenter, non-interventional post-authorization study assessed the characteristics, clinical management, and outcome of CLL and FL patients receiving idelalisib in routine clinical practice in Germany.

Patients: Observational study in CLL and FL patients treated with idelalisib between September 2015 and December 2020.